AI-programmable DNA switches for selective, safe, and adaptive gene therapy
10 experimental cycles
6–12 months until first licence
Seed round: $8 M
“We build the foundation for smart and safe gene therapy — from design to validation.”
Building a Smarter, Safer Future for Gene Therapy
- Cancer affects everyone — the goal is treatment that’s effective yet gentle.
- Each experiment is measured by results and progress, not promises.
- The platform ensures transparency, reproducibility, and continuous improvement.
- Every cycle brings us closer to fully customizable gene therapy.
Key Differentiators
OncoSwitch pairs AI with high-throughput wet-lab validation (MPRA) to design regulatory switches that selectively activate in disease tissue while remaining silent in normal tissue.
Proprietary data
Biological AI
Validated IP
Roadmap Timeline (24-Months Structure)
Development Phases 2026–2028
Phase 01
Preparation
Setup team, Platform, Libraries
Phase 02
MPRA+AI Models
MPRA cycles, AI baseline, Closed loop
Phase 03
MVP & BD
MVP switches, Assays, BD outreach
Phase 04
Pilot
Production library, Validation, Pilots
Phase 05
Licensing
IP, Licensing, Series A prep
Validation Pathway
Every DNA switch starts with AI and high-throughput MPRA, then progresses through increasingly predictive biological models.
Cell line
High-throughput screening
Organoids
Human tissue context
Primary cells
Native cell validation
In vivo
Therapeutic confirmation
Investor Value / Business Model
Revenue Sources:
Paid Pilots
Platform licensing
Milestones
Royalties
Upsell Path: Validation → Collaboration → Licensing.
Partner With Us
Let’s Build the Future of Gene Therapy Together
We welcome biotech partners, research institutions, and investors who share our vision of smarter, safer therapy.
Our platform will offer transparency, real-time data access, and co-development opportunities.
Together, we can accelerate the transition from experimental validation to real-world therapies.
